newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
Bristol Myers Squibb's oral drug mezigdomide is making waves in the medical community.
Mezigdomide reduced the risk of multiple myeloma progression or death by 52% in trials.
KEY POINTS
CVS Health has restored insurance coverage for Eli Lilly's Zepbound and newly approved pill Foundayo.
CVS's coverage decision resulted from price negotiations involving Novo Nordisk, its direct competitor.
A U.S. proposal for an Ebola quarantine facility in Kenya was halted by local judicial action.
Bristol Myers Squibb's innovative oral drug mezigdomide is making waves in the medical community. In a late-stage trial, the drug effectively delayed the progression of multiple myeloma in patients unresponsive to other treatments, cutting the risk of disease progression or death by 52%.
CVS Health reinstated coverage for Eli Lilly's obesity drug Zepbound along with its newly approved obesity pill, Foundayo. This decision comes after negotiations regarding pricing with competing drugmaker Novo Nordisk, highlighting the strategic battles within the pharmaceutical industry.
In Kenya, a U.S. plan to establish an Ebola quarantine facility met judicial roadblocks, questioning its potential public health risks. The suspension reflects ongoing global concerns about Ebola's spread and the measures being undertaken to control it.
(With inputs from agencies.)